May 23, 2023
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
Read more »May 11, 2023
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
Read more »May 10, 2023
Avalyn Pharma Presenting at BioEquity Europe
Read more »April 11, 2023
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
Read more »March 30, 2023
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Read more »March 23, 2023
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
Read more »November 28, 2022
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »October 17, 2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Read more »October 27, 2021
Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Read more »May 24, 2021
Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »October 16, 2020
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »April 27, 2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »May 15, 2017
Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Read more »October 31, 2016
IPF Up and Comers Look to Add On Rather Than Compete
Read more »September 3, 2014
Will Little-Known Company’s Inhaled Candidate Take Down InterMune-Roche’s Pirfenidone?
Read more »August 5, 2014
Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Read more »May 13, 2014
Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Read more »April 21, 2014
Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Read more »June 5, 2013
Genoa Pharmaceuticals and McMaster University Demonstrate in Vivo Benefit of Inhaled Pirfenidone Offering Greater Pulmonary Fibrosis Efficacy Than Oral Therapy
Read more »January 16, 2013
Genoa Pharmaceuticals and McMaster University to Collaborate on Idiopathic Pulmonary Fibrosis Research
Read more »
